[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  ClearSight AI [@ClearSightAI](/creator/twitter/ClearSightAI) on x XXX followers Created: 2025-07-24 20:30:00 UTC $EW Q2 FY2025 Earnings: Strong Sales Beat & Raised Full-Year Outlook 🫀📈 Edwards Lifesciences ($EW) posted solid Q2 growth, lifted sales/EPS guidance, and continues expanding its TAVR & TMTT leadership: ✅ Adjusted EPS: $XXXX (vs. $XXXX est.) ❌ GAAP EPS: $XXXX (vs. $XXXX est.) ✅ Revenue: $1.53B (vs. $1.49B est.) Outlook Raised: 🔭 📌 FY Sales: $5.9B–$6.1B (from $5.8B–$6.1B) 📌 FY Adjusted EPS: High end of $2.40–$2.50 📌 TAVR growth: 6%–7% (from 5%–7%) 📌 Q3 Sales: $1.46B–$1.54B | Adj. EPS: $0.54–$0.60 Highlights: 💡 🫀 TAVR sales: +8.9% to $4.3B–$4.5B FY guide 🧬 TMTT sales: $134.5M, led by PASCAL & EVOQUE 🩺 Surgical sales: +7.7% YoY 🧪 SAPIEN M3 & KONECT received CE Mark in EU 💰 Cash: ~$3B | Debt: ~$600M 📊 Adj. Op Margin: XXXX% | Gross Margin: XXXX% Challenges: ⚠️ 📉 GAAP EPS miss due to $47M impairment 💸 SG&A up to $502M | R&D rose to $276M 📉 Gross margin down from XXXX% YoY 📉 Net income: $336M (vs. $364M YoY) 📈 Tax provision increased 3x YoY to $64.3M $EW beat estimates and raised guidance while expanding its global regulatory approvals—positioning itself as a leader in structural heart innovations. 💓 #Earnings #MedTech #TAVR #EW #Investing XXX engagements  **Related Topics** [$58b](/topic/$58b) [$61b](/topic/$61b) [$59b](/topic/$59b) [$149b](/topic/$149b) [$153b](/topic/$153b) [eps](/topic/eps) [$ew](/topic/$ew) [coins ai](/topic/coins-ai) [Post Link](https://x.com/ClearSightAI/status/1948480810249519191)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
ClearSight AI @ClearSightAI on x XXX followers
Created: 2025-07-24 20:30:00 UTC
$EW Q2 FY2025 Earnings: Strong Sales Beat & Raised Full-Year Outlook 🫀📈 Edwards Lifesciences ($EW) posted solid Q2 growth, lifted sales/EPS guidance, and continues expanding its TAVR & TMTT leadership: ✅ Adjusted EPS: $XXXX (vs. $XXXX est.) ❌ GAAP EPS: $XXXX (vs. $XXXX est.) ✅ Revenue: $1.53B (vs. $1.49B est.)
Outlook Raised: 🔭 📌 FY Sales: $5.9B–$6.1B (from $5.8B–$6.1B) 📌 FY Adjusted EPS: High end of $2.40–$2.50 📌 TAVR growth: 6%–7% (from 5%–7%) 📌 Q3 Sales: $1.46B–$1.54B | Adj. EPS: $0.54–$0.60
Highlights: 💡 🫀 TAVR sales: +8.9% to $4.3B–$4.5B FY guide 🧬 TMTT sales: $134.5M, led by PASCAL & EVOQUE 🩺 Surgical sales: +7.7% YoY 🧪 SAPIEN M3 & KONECT received CE Mark in EU 💰 Cash: ~$3B | Debt: ~$600M 📊 Adj. Op Margin: XXXX% | Gross Margin: XXXX%
Challenges: ⚠️ 📉 GAAP EPS miss due to $47M impairment 💸 SG&A up to $502M | R&D rose to $276M 📉 Gross margin down from XXXX% YoY 📉 Net income: $336M (vs. $364M YoY) 📈 Tax provision increased 3x YoY to $64.3M
$EW beat estimates and raised guidance while expanding its global regulatory approvals—positioning itself as a leader in structural heart innovations. 💓 #Earnings #MedTech #TAVR #EW #Investing
XXX engagements
